Articles tagged "Rejection"

2022 American Transplant Congress
Rejection After Liver Transplantation: What Can We Learn from Transcriptomic Analysis?
H. J. Braun¹, D. Amara², A. Zarinsefat¹, G. Szabo¹, Z. Laszik¹, P. Stock¹, N. Ascher¹
¹University of California, San Francisco, San Francisco, CA, ²UCLA, Los Angeles, CA
*Purpose: Acute cellular rejection (ACR) can occur at any time following liver transplantation (LT); initial ACR within 6 months is most common and occurs in…
2022 American Transplant Congress
Diagnostic Performance of Donor-Derived Cell-Free DNA Assay (AlloSure®) in Kidney Transplant Recipients with Graft Dysfunction: A Single Center Study
M. S. Naseer¹, H. Shokouh-Amiri², T. Creamer¹, R. McMillan², S. Tandukar¹, D. Aultman¹, G. B. Zibari¹, N. Singh¹
¹Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Health System, Shreveport, LA, ²John C. McDonald Regional Transplant Center - Willis Knighton Health System, Shreveport, LA
*Purpose: Circulating donor-derived cell-free DNA (dd-cf-DNA) is a non-invasive biomarker of kidney allograft injury with a high negative predictive value for ruling out active rejection…
2022 American Transplant Congress
Utility of Donor Derived Cell-Free DNA in Liver Transplantation
A. Zarrinpar, D. Lewis, C. Warren, S. Duarte
Surgery, University of Florida, Gainesville, FL
*Purpose: As a non-invasive measure of allograft injury, quantifying the fraction of donor-derived cell-free DNA (dd-cfDNA) has proven to be useful technique in kidney transplantation.…
2022 American Transplant Congress
Trends in Donor Derived Cell Free DNA Before and After Cellular and Antibody Mediated Rejection
K. Guo¹, J. Friedewald¹, C. Rebello¹, B. Kinsella¹, S. Park², L. Zhao¹
¹Northwestern University, Chicago, IL, ²Transplant nephrology, Northwestern University, Chicago, IL
*Purpose: The TRAC dd-cfDNA test was developed to detect acute kidney transplant rejection but can also detect subclinical rejection with improved performance in antibody-mediated rejection…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA Testing in Kidney Transplantation: Do One-Month Values Have Any Prognostic Significance?
B. K. Sharda¹, M. Garner¹, A. Farney¹, G. Orlando², J. Rogers², C. Jay³, A. Daniel¹, A. Guiterrez¹, N. Sakhovskaya¹, R. Stratta¹
¹ATRIUM HEALTH Wake Forest Baptist Medical Center, Winston Salem, NC, ²Wake Forest Baptist Medical Center, Winston Salem, NC, ³Wake Forest Baptist Health, Winston-Salem, NC
*Purpose: Plasma-based donor-derived cell-free DNA (dd-cfDNA) assays have been proposed as an alternative to percutaneous renal allograft biopsy which is the current gold standard for…
2022 American Transplant Congress
Utility of Four-Point Mycophenolate Mofetil Testing in a Pediatric Kidney Transplant Population
S. Sadiq, P. Brakeman, J. Brennan, E. Black
Pediatric Nephrology, UCSF, San Francisco, CA
*Purpose: While there is randomized, multicenter data in adults that area under the time concentration curve (AUC) measurements for Mycophenolate Mofetil (MMF) can direct dosing…
2022 American Transplant Congress
Induction Immunosuppression in ABO-Incompatible Liver Transplant Recipients
S. Shaikh¹, I. Hasan¹, N. Kaur²
¹Keck Medicine of USC, Los Angeles, CA, ²Keck School of Medicine, Los Angeles, CA
*Purpose: ABO-incompatible (ABO-i) liver transplantation (LT) has been associated with an increased risk of AMR, as well as poor patient and graft survival. With advances…
2022 American Transplant Congress
Significance of C4d Expression in Peritubular Capillary Concurrent with Microvascular Inflammation in For-Cause Biopsies of ABO-Incompatible Renal Allografts
H. Cho¹, C. Baek², H. Kim³
¹Department of Pathology, Asan Medical Center, Seoul, Korea, Republic of, ²Department of Internal Medicine, Asan Medical Center, Seoul, Korea, Republic of, ³Asan Medical Center, Seoul, Korea, Republic of
*Purpose: ABO incompatible (ABOi) kidney transplantation (KT) has been increasing due to severe organ shortages. Pathologic diagnosis of antibody-mediated rejection (ABMR) in ABOi patients is…
2022 American Transplant Congress
Valganciclovir for the Prevention of CMV After Treatment of Rejection with Anti-Lymphocyte Depleting Antibodies in Kidney Transplant Recipients
M. Mahoney, J. Nelson, E. Kincaide, R. Hall, H. Sweiss
University Health, San Antonio, TX
*Purpose: To evaluate efficacy and safety of valganciclovir for prevention of cytomegalovirus (CMV) after treatment of rejection with anti-lymphocyte depleting antibodies (ALA).*Methods: This single-center retrospective…
2022 American Transplant Congress
The Trajectory of Donor-Derived Cell-Free DNA (dd-cfDNA) Complements the Baseline Measurements in Heart Transplant Surveillance for Rejection
P. Shah¹, R. Cheng², H. Eisen³, B. D. Lowes⁴, L. Lourenco Jenkins⁵, Y. Fu⁵, K. Qu⁵, J. Teuteberg⁶, E. DePasquale⁷
¹Inova Heart and Vascular Institute, Falls Church, VA, ²University of Washington Heart Institute, Seattle, WA, ³Pennsylvania State University, Hershey, PA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵CareDx, Brisbane, CA, ⁶Stanford University, Stanford, CA, ⁷University of Southern California, Los Angeles, CA
*Purpose: Changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the dd-cfDNA…